Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions

References

• Gomez SM, Caniza M, Fynn A, et al. Fungal infections in hematopoietic stem cell transplantation in children at a pediatric children’s hospital in Argentina. Transpl Infect Dis. 2018;20:e12913.
   PubMed Web of Science ®Google Scholar
• Iosifidis E, Papachristou S, Roilides E. Advances in the Treatment of Mycoses in Pediatric Patients. J Fungi (Basel). 2018;4(4):115.
   Google Scholar
• Shariati A, Moradabadi A, Chegini Z, et al. An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies. Infect Drug Resist. 2020;13:2329–2354.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.
   PubMed Web of Science ®Google Scholar
• Cugno C, Cesaro S. Epidemiology, risk factors, and therapy of candidemia in pediatric hematological patients. Pediatr Rep. 2012;4(1):e9.
   PubMedGoogle Scholar
• Tsai M-H, Hsu J-F, Yang L-Y, et al. Candidemia due to uncommon Candida species in children: new threat and impacts on outcomes. Sci Rep. 2018;8(1):15239.
   PubMed Web of Science ®Google Scholar
• De Pauw BE. Fungal infections: diagnostic problems and choice of therapy. Leukemia Supplements. 2012;1(Suppl S2):S22–3.
   PubMedGoogle Scholar
• Kyriakidis I, Tragiannidis A, Munchen S, et al Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf. 2017;16(2):149–165.
   PubMed Web of Science ®Google Scholar
• Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am. 2000;131(1):159–191.
   Web of Science ®Google Scholar
• Nivoix Y, Ledoux MP, Herbrecht R. Antifungal Therapy: new and Evolving Therapies. Semin Respir Crit Care Med. 2020;41:158–174.
   PubMed Web of Science ®Google Scholar
• Loghman-Adham M, Kiu Weber CI, Ciorciaro C, et al. Detection and management of nephrotoxicity during drug development. Expert Opin Drug Saf. 2012 Jul;11(4):581–596.
   PubMed Web of Science ®Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179–184.
   PubMed Web of Science ®Google Scholar
• Rocha PN, Kobayashi CD, De Carvalho Almeida L, et al. Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria. Antimicrob Agents Chemother. 2015;59:4759–4769.
   PubMed Web of Science ®Google Scholar
• Tiong HY, Huang P, Xiong S, et al. Drug-induced nephrotoxicity: clinical impact and preclinical in vitro models. Mol Pharm. 2014;11:1933–1948.
   PubMed Web of Science ®Google Scholar
• Hazen E, Brown R. Two antifungal agents produced by a soil actinomycete. Science. 1950;112:423.
   PubMed Web of Science ®Google Scholar
• Wang JL, Chang CH, Young-Xu Y, et al. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54:2409–2419.
   PubMed Web of Science ®Google Scholar
• Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45:737–779.
   PubMed Web of Science ®Google Scholar
• Falci DR, Da Rosa FB, Pasqualotto AC. Hematological toxicities associated with amphotericin B formulations. Leuk Lymphoma. 2015;56:2889–2894.
   PubMed Web of Science ®Google Scholar
• Shigemi A, Matsumoto K, Ikawa K, et al. Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia. Int J Antimicrob Agents. 2011;38:417–420.
   PubMed Web of Science ®Google Scholar
• Carlson MA, Condon RE. Nephrotoxicity of amphotericin B. J Am Coll Surg. 1994;179:361–381.
   PubMed Web of Science ®Google Scholar
• Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf. 1990;5:94–108.
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73:919–934.
   PubMed Web of Science ®Google Scholar
• Sawaya BP, Weihprech TH, Campbell WR, et al. Direct basal vasoconstriction as a possible cause for amphotericin B nephrotoxicity in rats. J Clin Inves. 1991;87:2097–2107.
   PubMed Web of Science ®Google Scholar
• Suschek CV, Bonmann E, Kleinert H, et al. Amphotericin B severely affects expression and activity of the endothelial constitutive nitric oxide synthase involving altered mRNA stability. Br J Pharmacol. 2000;131:473–481.
   PubMed Web of Science ®Google Scholar
• Chai LY, Netea MG, Tai BC, et al. An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 2013;68:1655–1659.
   PubMed Web of Science ®Google Scholar
• Butler WT, Bennett JE, Alling DW, et al. Nephrotoxicity of amphotericin B. Early and late effects in 81 patients. Ann Intern Med. 1964;61:175–187.
   PubMed Web of Science ®Google Scholar
• Bagnis CI, Deray G. Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transplant. 2002;13:481–491.
   PubMedGoogle Scholar
• Fisher MA, Talbot GH, Maislin G, et al. Risk factors for amphotericin B-associated nephrotoxicity. Am J Med. 1989;87:547–552.
   PubMed Web of Science ®Google Scholar
• Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29:1402–1407.
   PubMed Web of Science ®Google Scholar
• Nett JE, Andes DR. Antifungal Agents: spectrum of Activity, Pharmacology, and Clinical Indications. Infect Dis Clin North Am. 2016;30:51–83.
   PubMed Web of Science ®Google Scholar
• Mourad A, Perfect JR. Tolerability profile of the current antifungal armory. J Antimicrob Chemother. 2018;73(suppl_1):i26–i32.
   PubMed Web of Science ®Google Scholar
• Laniado-Laborín R, Cabrales-Vargas MN, Amphotericin B. side effects and toxicity. Rev Iberoam Micol. 2009;26:223–227.
   PubMed Web of Science ®Google Scholar
• França FD, Ferreira AF, Lara RC, et al. Alteration in cellular viability, pro-inflammatory cytokines and nitric oxide production in nephrotoxicity generation by Amphotericin B: involvement of PKA pathway signaling. J Appl Toxicol. 2014;34(12):1285–1292.
   PubMed Web of Science ®Google Scholar
• Branch RA. Prevention of Amphotericin B—Induced Renal Impairment. Arch Intern Med. 1988;148(11):2389–2394.
   PubMed Web of Science ®Google Scholar
• Turcu R, Patterson MJ, Omar S. Influence of sodium intake on Amphotericin B-induced nephrotoxicity among extremely premature infants. Pediatr Nephrol. 2009;24(3):497–505.
   PubMed Web of Science ®Google Scholar
• Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004;54(4):803–808.
   PubMed Web of Science ®Google Scholar
• Eriksson U. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001;322(7286):579–582.
   PubMed Web of Science ®Google Scholar
• Karimzadeh I, Khalili H, Sagheb MM, et al. A double-blinded, placebo-controlled, multicenter clinical trial of N -acetylcysteine for preventing amphotericin B-induced nephrotoxicity. Expert Opin Drug Metab Toxicol. 2015;11(9):1345–1355.
   PubMed Web of Science ®Google Scholar
• Dutta A, Palazzi DL. Risk Factors of Amphotericin B Toxicity in the Nonneonatal Pediatric Population. Pediatr Infect Dis J. 2012;31(9):910–914.
   PubMed Web of Science ®Google Scholar
• Groll AH, Müller F-M, Piscitelli SC, et al. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin Padiatr. 1998 Jul-Aug;210(4):264–273.
   PubMed Web of Science ®Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis. 1996 May;22(Suppl Supplement_2):S133–44.
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Pappas PG, Sobel JD, et al., Eds. Essentials of Clinical Mycology. New York, NY: Springer; 2014.
   Google Scholar
• Caillot D, Casasnovas O, Solary E, et al. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients. J Antimicrob Chemother. 1993;31(1):161–169.
   PubMed Web of Science ®Google Scholar
• Ayestaran A, Lopez RM, Montoro JB, et al Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob Agents Chemother. 1996;40(3):609–612.
   PubMed Web of Science ®Google Scholar
• Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother. 1996;30(4):409–412.
   PubMed Web of Science ®Google Scholar
• Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy. 1999;19(3):306–323.
   PubMed Web of Science ®Google Scholar
• Robinson RF, Nahata MC. A comparative review of conventional and lipid formulations of amphotericin B. J Clin Pharm Ther. 1999;24(4):249–257.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Whitcomb P, Piscitelli S, et al Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother. 1997;41(9):1944–1948.
   PubMed Web of Science ®Google Scholar
• Villani P, Regazzi MB, Maserati R, et al Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients. Arzneimittelforschung. 1996;46(4):445–449.
   PubMed Web of Science ®Google Scholar
• Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother. 2006;50(10):3418–3423.
   PubMed Web of Science ®Google Scholar
• Johnson PC, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105–109.
   PubMed Web of Science ®Google Scholar
• Mistro S, Maciel Ide M, De Menezes RG, et al., Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 54(12): 1774–1777. 2012.
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35(4):359–366.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340(10):764–771.
   PubMed Web of Science ®Google Scholar
• White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27(2):296–302.
   PubMed Web of Science ®Google Scholar
• Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98(3):711–718.
   PubMed Web of Science ®Google Scholar
• Moghnieh R, El-Rajab N, Abdallah DI, et al Retrospective Analysis on the Use of Amphotericin B Lipid Complex in Neutropenic Cancer Patients with Suspected Fungal Infections in Lebanon, a Single Center Experience and Review of International Guidelines. Front Med (Lausanne). 2015;2:92.
   PubMed Web of Science ®Google Scholar
• Andrew EC, Curtis N, Coghlan B, et al. Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations. Br J Clin Pharmacol. 2018;84(5):1006–1012.
   PubMed Web of Science ®Google Scholar
• Alexander BD, Wingard JR. Study of Renal Safety in Amphotericin B Lipid Complex–Treated Patients. Clin Infect Dis. 2005;40(Suppl. Supplement_6):S414–421.
   PubMed Web of Science ®Google Scholar
• Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol. 2008;46(2):97–112.
   PubMed Web of Science ®Google Scholar
• Tonin FS, Steimbach LM, Borba HH. Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis. J Pharm Pharmacol. 2017;69(12):1672–1683.
   PubMed Web of Science ®Google Scholar
• Wade RL, Chaudhari P, Natoli JL, et al., Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagn Microbiol Infect Dis. 76(3): 361–367. 2013.
   PubMed Web of Science ®Google Scholar
• Steimbach LM, Tonin FS, Virtuoso S, et al., Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis. Mycoses. 60(3): 146–154. 2017.
   PubMed Web of Science ®Google Scholar
• Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther. 2003;25(5):1295–1320.
   PubMed Web of Science ®Google Scholar
• Annino L, Chierichini A, Anaclerico B, et al. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother. 2013;57:2596–2602.
   PubMed Web of Science ®Google Scholar
• Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103:205–212.
   PubMed Web of Science ®Google Scholar
• Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis. 1998;31:780–785.
   PubMed Web of Science ®Google Scholar
• Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy. 2001;21:1107–1114.
   PubMed Web of Science ®Google Scholar
• Cagatay AA, Cosan F, Karadeniz A, et al. The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases. Mycoses. 2008;51:328–335.
   PubMed Web of Science ®Google Scholar
• Hachem RY, Boktour MR, Hanna HA, et al Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer. 2008;112:1282–1287.
   PubMed Web of Science ®Google Scholar
• Groll AH, Silling G, Young C, et al. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2010;54:4143–4149.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Faucher C, Fürst S, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39:301–306.
   PubMed Web of Science ®Google Scholar
• Roman E, Osunkwo I, Militano O, et al. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer. 2008;50:325–330.
   PubMed Web of Science ®Google Scholar
• White MH, Anaissie EJ, Kusne S, et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergil- losis. Clin Infect Dis. 1997;24:635–642.
   PubMed Web of Science ®Google Scholar
• De Souza MC, Santos AG, Reis AM. Adverse Drug Reactions in Patients Receiving Systemic Antifungal Therapy at a High-Complexity Hospital. J Clin Pharmacol. 2016;56:1507–1515.
   PubMed Web of Science ®Google Scholar
• Miller CB, Waller EK, Klingemann HG, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant. 2004;33:543–548.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402.
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, Da Cunha CA, et al. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519–1527.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Pappas P, Winston DJ, et al. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–234.
   PubMed Web of Science ®Google Scholar
• Grazziotin LR, Moreira LB, Ferreira MAP. Comparative effectiveness and safety between amphotericin b lipid-formulations: a systematic review. Int J Technol Assess Health Care. 2018;34(3):343–351.
   PubMed Web of Science ®Google Scholar
• Falci DR, Da Rosa FB, Pasqualotto AC. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study. Mycoses. 2015;58(2):104–112.
   PubMed Web of Science ®Google Scholar
• Manzoni P, Galletto P, Rizzollo S, et al. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. Early Hum Dev. 2012;88(Suppl 2):S86–91.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46(1):150–156.
   PubMed Web of Science ®Google Scholar
• Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag. 2007;3(1):71–97.
   PubMedGoogle Scholar
• Denning DW, Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother. 2002;49(6):889–891.
   PubMed Web of Science ®Google Scholar
• Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J. 2009;28(12):1132–1135.
   PubMed Web of Science ®Google Scholar
• Puia-Dumitrescu M, Smith PB. Antifungal Drugs in Newborns and Children. Pediatr Clin North Am. 2017;64(6):1389–1402.
   PubMed Web of Science ®Google Scholar
• Tsekoura M, Ioannidou M, Pana Z-D, et al. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: a Meta-analysis. Pediatr Infect Dis J. 2019;38(1):42–49.
   PubMed Web of Science ®Google Scholar
• Vermes A. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46(2):171–179.
   PubMed Web of Science ®Google Scholar
• Lewis R, Bruggemann R, Padoin C Triazole antifungal therapeutic drug monitoring. 6th European Conference on Infections in Leukemia (ECIL-6). Sept 9, 2015. http://ecil-leukaemia.com/telechargements2015/ECIL6-Triazole-TDM-07-12-2015-Lewis-R-et-al.pdf (cited 2020 Nov 10
   Google Scholar
• Shafiei M, Peyton L, Hashemzadeh M, et al. History of the development of antifungal azoles: a review on structures, SAR, and mechanism of action. Bioorg Chem. 2020;104:104240.
   PubMed Web of Science ®Google Scholar
• Kaushik A, Kest H The Role of Antifungals in Pediatric Critical Care Invasive Fungal Infections. Crit Care Res Pract. 2018;2018:8469585.
   PubMed Web of Science ®Google Scholar
• Whaley SG, Berkow EL, Rybak JM, et al. Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Front Microbiol. 2017;7:2173.
   PubMed Web of Science ®Google Scholar
• Kumar A, Jha A. Anticandidal Agents. Amsterdam, Netherlands: Academic Press; 2017.
   Google Scholar
• Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev. 2018;20(4):40–79.
   Google Scholar
• Cleveland AA, Farley MM, Harrison LH, et al. Changes in Incidence and Antifungal Drug Resistance in Candidemia: results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012;55(10):1352–1361.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. Journal of Clinical Microbiology. 2003;41(5):2176–2179.
   PubMed Web of Science ®Google Scholar
• Forsberg K, Woodworth K, Walters M, et al. Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Med Mycol. 2019 Jan 1;57(1):1–12.
   PubMed Web of Science ®Google Scholar
• Cota JM, Burgess DS. Antifungal Dose Adjustment in Renal and Hepatic Dysfunction: pharmacokinetic and Pharmacodynamic Considerations. Curr Fungal Infect Rep. 2010;4(2):120–128.
   Google Scholar
• Doncker PD, Pande S, Richarz U, et al. Itraconazole: what clinicians should know? Indian J Drugs Dermatol. 2017;3(1):4–10.
   Google Scholar
• Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68–88.
   PubMed Web of Science ®Google Scholar
• Itraconazole. Summary of product characteristics. https://www.ema.europa.eu/en/documents/psusa/itraconazole-list-nationally-authorised-medicinal-products-psusa/00001798/201703_en.pdf
   Google Scholar
• Greer ND. Voriconazole: the newest triazole antifungal agent. Proc (Bayl Univ Med Cent). 2004;351(14):1391–1402.
   Google Scholar
• Groll AH, Townsend R, Desai A, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017;19(5):e12751.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Böhme A, Reichert D, et al. Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol. 1964 Mar;61(2):126–131.
   Web of Science ®Google Scholar
• Zonios DI, Gea‐Banacloche J, Childs R, et al. Hallucinations during Voriconazole Therapy. Clin Infect Dis. 1999;29(1):e7–e10.
   Web of Science ®Google Scholar
• Zonios D, Yamazaki H, Murayama N, et al. Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype. J Infect Dis. 2014;209(12):1941–1948.
   PubMed Web of Science ®Google Scholar
• Williams K, Mansh M, Chin-hong P, et al. Voriconazole-Associated Cutaneous Malignancy: a Literature Review on Photocarcinogenesis in Organ Transplant Recipients. Clin Infect Dis. 2014;58(7):997–1002.
   PubMed Web of Science ®Google Scholar
• Cowen EW, Nguyen JC, Miller DD, et al. Chronic Phototoxicity and Aggressive Squamous Cell Carcinoma of the Skin in Children and Adults During Treatment with Voriconazole. J Am Acad Dermatol. 2010;62(1):31–37.
   PubMed Web of Science ®Google Scholar
• Malani AN, Kerr L, Obear J, et al. Alopecia and Nail Changes Associated With Voriconazole Therapy. Clin Infect Dis. 2014;59(3):e61–65.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Lombardi LR, Shields RK, et al. Administration of Voriconazole in Patients With Renal Dysfunction. Clin Infect Dis. 2012;54(7):913–921.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Kwon J-C, Park C, et al., Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether β-cyclodextrin in haematological patients with renal impairment. Mycoses. 59(10): 644–651. 2016.
   PubMed Web of Science ®Google Scholar
• Abel S, Allan R, Gandelman K, et al. Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally??Impaired Subjects. Clin Drug Investig. 2008;28(7):409–420.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Viviani M-A, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38(Suppl s1):335–347.
   PubMed Web of Science ®Google Scholar
• Groll AH, Kolve H, Ehlert K, et al. Pharmacokinetic interaction between voriconazole and cyclosporine A following allogeneic bone marrow transplantation. J Antimicrob Chemother. 2004;53:113–114.
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005;3:467–487.
   PubMedGoogle Scholar
• Groll AH, Abdel-Azim H, Lehrnbecher T, et al. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. Int J Antimicrob Agents. 2020;56:106084.
   PubMed Web of Science ®Google Scholar
• Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 2010;18:195–204.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Davis MR, Wittenberg R, et al. Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism. Clin Infect Dis. 2020;70(12):2593–2598.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007 Jan 25;356(4):335–347.
   PubMed Web of Science ®Google Scholar
• Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol. 2005;45:185–192.
   PubMed Web of Science ®Google Scholar
• Nickless JR, Bridger KE, Vora SB, et al. Evaluation of Intravenous Posaconazole Dosing and Pharmacokinetic Target Attainment in Pediatric Patients. J Pediatric Infect Dis Soc. 2019;8(4):365–367.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case–control analysis. Lancet Infect Dis. 2016;16:828–837.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387:760–769.
   PubMed Web of Science ®Google Scholar
• Groll AH, Desai A, Han D, et al. Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults. Clin Pharmacol Drug Dev. 2017;6:76–85.
   PubMed Web of Science ®Google Scholar
• Denis J, Ledoux MP, Nivoix Y, et al. Isavuconazole: a new broad-spectrum azole. Part 1: in vitro activity. J Mycol Med. 2018;28:8–14.
   PubMed Web of Science ®Google Scholar
• Wilson DT, Dimondi VP, Johnson SW, et al. Role of isavuconazole in the treatment of invasive fungal infections. Ther Clin Risk Manag. 2016;12:1197–1206.
   PubMed Web of Science ®Google Scholar
• Cornu M, Bruno B, Loridant S, et al. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report. BMC Pharmacol Toxicol. 2018;19:81.
   PubMed Web of Science ®Google Scholar
• Barg AA, Malkiel S, Bartuv M, et al. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer. 2018;65:e27281.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Mullane KM, Ostrosky-Zeichner L, et al. Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018;61:518–533.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Moriyama B, Petraitiene R, et al. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. Clin Pharmacokinet;2018:1–9. DOI:https://doi.org/10.1007/s40262-017-0571-z.
   Google Scholar
• Darnaud L, Lamoureux F, Godet C, et al. Isavuconazole Kinetic Exploration for Clinical Practice. Drugs R D. 2018;18:317–321.
   PubMed Web of Science ®Google Scholar
• Townsend RW, Akhtar S, Alcorn H, et al. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017;73:669–678.
   PubMed Web of Science ®Google Scholar
• Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300.
   PubMed Web of Science ®Google Scholar
• Bongomin F, Maguire N, Moore CB, et al. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: a retrospective comparison of rates of adverse events. Mycoses. 2019;62:217–222.
   PubMed Web of Science ®Google Scholar
• Guinea J, Bouza E. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol. 2008 Dec;3(6):603–615.
   PubMed Web of Science ®Google Scholar